Atomi Financial Group Inc. Raises Stake in Amgen Inc. (NASDAQ:AMGN)

Atomi Financial Group Inc. boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 38.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,171 shares of the medical research company’s stock after buying an additional 1,435 shares during the quarter. Atomi Financial Group Inc.’s holdings in Amgen were worth $1,616,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. United Community Bank acquired a new stake in Amgen during the fourth quarter worth about $29,000. Horizon Financial Services LLC acquired a new stake in shares of Amgen during the 1st quarter worth approximately $28,000. Delos Wealth Advisors LLC increased its holdings in shares of Amgen by 2,500.0% during the 4th quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 100 shares in the last quarter. Bbjs Financial Advisors LLC acquired a new position in shares of Amgen in the 2nd quarter valued at $33,000. Finally, Western Pacific Wealth Management LP purchased a new stake in Amgen during the fourth quarter worth $37,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. BMO Capital Markets upped their price objective on shares of Amgen from $336.00 to $355.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Wells Fargo & Company lowered Amgen from an “overweight” rating to an “equal weight” rating and raised their price objective for the company from $320.00 to $335.00 in a report on Wednesday, August 7th. William Blair upgraded Amgen from a “market perform” rating to an “outperform” rating in a research report on Friday, May 3rd. StockNews.com upgraded Amgen from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Finally, Mizuho boosted their price target on shares of Amgen from $223.00 to $235.00 and gave the stock a “neutral” rating in a report on Thursday, May 9th. Eleven equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, Amgen currently has a consensus rating of “Moderate Buy” and a consensus price target of $326.89.

Amgen Trading Up 0.0 %

Shares of Amgen stock traded up $0.15 during mid-day trading on Tuesday, hitting $326.93. The stock had a trading volume of 1,090,542 shares, compared to its average volume of 2,568,934. The firm has a market cap of $175.38 billion, a P/E ratio of 46.70, a price-to-earnings-growth ratio of 2.78 and a beta of 0.58. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96. The firm has a 50-day moving average of $323.17 and a two-hundred day moving average of $299.76. Amgen Inc. has a 12-month low of $248.38 and a 12-month high of $346.85.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a return on equity of 156.21% and a net margin of 12.74%. The business had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. During the same period last year, the business earned $5.00 EPS. Amgen’s revenue was up 20.1% compared to the same quarter last year. Sell-side analysts forecast that Amgen Inc. will post 19.5 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 2.75%. The ex-dividend date was Friday, August 16th. Amgen’s dividend payout ratio (DPR) is presently 128.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.